Lonza to acquire sterile fill and finish facility from Novartis

On July 1, 2019, SIX-listed Lonza Group AG announced that it has entered into a binding agreement regarding the acquisition of the sterile fill and finish facility of Novartis in Stein (Canton Aargau). The new facility will enable Lonza Pharma & Biotech to build on existing parenteral drug product development and testing capabilities and offer end-to-end services to its customers for clinical supply and launch.

Lenz & Staehelin is advising Lonza in this transaction.